Neuburgh Advisers LLC lowered its stake in shares of Qiagen NV (NYSE:QGEN) by 46.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,016 shares of the company’s stock after selling 1,728 shares during the period. Neuburgh Advisers LLC’s holdings in Qiagen were worth $69,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds also recently added to or reduced their stakes in QGEN. Massachusetts Financial Services Co. MA boosted its holdings in Qiagen by 4.0% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 12,615,185 shares of the company’s stock worth $434,593,000 after buying an additional 481,606 shares in the last quarter. BlackRock Inc. boosted its holdings in Qiagen by 5.4% during the fourth quarter. BlackRock Inc. now owns 6,607,877 shares of the company’s stock worth $227,642,000 after buying an additional 336,763 shares in the last quarter. Bellevue Group AG raised its position in Qiagen by 224.4% during the fourth quarter. Bellevue Group AG now owns 435,299 shares of the company’s stock worth $14,996,000 after acquiring an additional 301,110 shares during the last quarter. Brown Advisory Inc. acquired a new position in Qiagen during the fourth quarter worth about $8,156,000. Finally, Hardman Johnston Global Advisors LLC raised its position in Qiagen by 5.5% during the fourth quarter. Hardman Johnston Global Advisors LLC now owns 4,407,084 shares of the company’s stock worth $151,824,000 after acquiring an additional 229,824 shares during the last quarter. 64.77% of the stock is currently owned by hedge funds and other institutional investors.
NYSE:QGEN opened at $39.93 on Wednesday. The company has a quick ratio of 2.05, a current ratio of 2.22 and a debt-to-equity ratio of 0.63. The company has a market capitalization of $8.95 billion, a PE ratio of 29.80, a PEG ratio of 2.47 and a beta of 0.91. Qiagen NV has a 1-year low of $31.10 and a 1-year high of $40.19.
A number of brokerages have issued reports on QGEN. UBS Group began coverage on shares of Qiagen in a research report on Friday, March 15th. They set a “neutral” rating and a $42.00 target price for the company. Deutsche Bank restated a “buy” rating on shares of Qiagen in a research report on Tuesday, January 29th. Finally, Jefferies Financial Group restated a “neutral” rating on shares of Qiagen in a research report on Monday, January 21st. Eight analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $41.17.
QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions.
Featured Story: Put Option Volume
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.